Topics

Companies Related to "International Randomized Study to Compare CyberKnife Stereotactic Radiotherapy With Surgical Resection In Stage I Non-small Cell Lung Cancer" [Most Relevant Company Matches] RSS

22:30 EDT 2nd April 2020 | BioPortfolio

Here are the most relevant search results for "International Randomized Study to Compare CyberKnife Stereotactic Radiotherapy With Surgical Resection In Stage I Non-small Cell Lung Cancer" found in our extensive corporate database of over 50,000 company records.

Showing "International Randomized Study Compare CyberKnife Stereotactic Radiotherapy With" Companies 1–25 of 4,100+

Extremely Relevant

RefleXion Medical

RefleXion is a privately-held company developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion machine is cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SR...


Relevant

European Randomized Study of Screening for Prostate Cancer (ERSPC)

ERSPC (European Randomized Study of Screening for Prostate Cancer)


Accuray

Accuray's history began when John R. Adler, MD, professor of neurosurgery and radiation oncology at Stanford University Medical Center, developed the CyberKnife® System in 1987 after completing a fellowship in Sweden with Lars Leksell, MD, the founder of radiosurgery. With the CyberKnife System, Adler’s vision was to develop a non-invasive robotic radiosurgery system with superior accuracy for ...

ACRO

Health outcomes aren't jeopardized when patients participate in randomized clinical trials of approved treatments, according to a new study. The results address misgivings some physicians have had about whether enrolling patients in a clinical trial might have a detrimental impact on their ability to receive individualized treatment. Conducted by a team led by Yale University's Dr. Cary P. Gross, ...

Biothera

Biothera, a privately held U.S. biotechnology company, is developing Imprime PGG, a late clinical stage biologic that modulates the immune response to cancer. Data from the most recent randomized phase 2 study of Imprime PGG in first line non-squamous non-small cell lung cancer (NSCLC) was featured as a late-breaking abstract in the Immunotherapy of Cancer...

Psimei Pharmaceuticals plc

Psimei Pharmaceuticals plc, founded in 2001, is a world leader in the development of Boron Cellular Radiotherapy (BCR) products. These are designed to significantly improve the clinical effectiveness of radiotherapy in the treatment of cancer. At present only 30% of cancer patients receiving radiotherapy are "cured". This equates to complete clinical responses for up to 5 years. Psimei is currentl...

ProCertus BioPharm, Inc.

ProCertus BioPharm is an oncology-based pharmaceutical company whose primary mission is to protect cancer patients against the side effects of chemotherapy and radiotherapy.ProCertus has established proof of concept in animal models for its product candidates, DermX, ProDermaCel™, and OralX, proprietary pharmaceuticals designed to reduce or eliminate the side effects associated with cancer thera...

Accuray Incorporated

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in ...

CyberKnife Society

Morse CyberKnife

Veterinary CyberKnife

CyberKnife Center of Miami

Veterinary CyberKnife Cancer Center

PAR Scientific A/S

PAR Scientific A/S was founded 1986 in Denmark. We are a subsidiary of S&S X-Ray Products Inc., USA. All development activities, both mechanical, electronics and software are taking place in Denmark. We manufacture high technology equipment for optimization of radiotherapy treatment and have more than 650 units installed in 375 radiotherapy centres throughout the world. Our Ideology is to develop,...

Adeona Pharmaceuticals, Inc.

Adeona (AMEX: AEN) is a pharmaceutical company developing new medicines for serious central nervous systems diseases. Adeona's primary strategy is to in-license clinical-stage drug candidates that have already demonstrated a certain level of clinical efficacy and develop them to an inflection point in valuation resulting in a significant development and marketing collaboration. Trimesta (estriol) ...

International Pharmaceutical Research Center

International Pharmaceutical Research Center the commitment to unparalleled Quality Research. Our strength is our recognition from sponsors, investigators, and study subjects in conducting each study with dedication and a personal touch, while maintaining strict compliance with good clinical practice.

CyberKnife Centers of Miami and Palm Beach

GlycoMark, Inc.

GlycoMark is an FDA-cleared blood test that reveals repeated episodes of postprandial hyperglycemia/glycemic variability by tracking postprandial glucose levels as they related to blood levels of the molecule 1,5-anhydroglucitol (1,5-AG). Multiple published studies indicate that 1,5-AG detects hyperglycemia not detected by the hemoglobin A1C test. A recent study conducted as part of the internat...

Augmenix, Inc.

Augmenix, Inc. is a privately held company based in Waltham, Mass., focused on the development and commercialization of implantable biomaterial based solutions for improved radiotherapy safety and/or efficacy. Augmenix's first product, SpaceOAR system is an injectable tissue spacer that will decrease rectal morbidity or enable improved efficacy in prostate radiotherapy. The company was founded in ...

Ameritox

The single-group, multi-dose study examined the ability of the Rx Guardian(SM) algorithm to differentiate among low, medium and high daily doses of OxyContin®. Oxycodone levels were detected in the urine of 36 healthy volunteers using a liquid chromatography-mass spectrometry (LC-MS-MS) assay. Participants were randomized to receive 80mg, 160mg or 240mg of daily OxyContin® to steady state cond...

Cytheris SA

Cytheris is a privately held clinical-stage biopharmaceutical company focused on research and development of therapies for immune modulation.  These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV, HCV, and HBV or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transp...

Anova Cancer Care

Anova Cancer Care serves Denver and the Rocky Mountain region with the world’s only robotic radiosurgery system designed to treat tumors anywhere in the body. Used by the nation’s leading hospitals and medical centers, the CyberKnife® System uses continual image guidance technology and computer controlled robotic mobility to track, detect and correct...

Devicor® Medical Products, Inc.

Devicor Medical Products, headquartered in Cincinnati, Ohio, has more than 400 employees around the world. As the global market leader, Devicor is committed to advancing technology to help clinicians accurately diagnose breast disease, such as breast cancer, through minimally invasive procedures. Devicor’s product portfolio includes the world-renowned...

&intoconnection

&intoconnection performed a study on what it means for people to be strongly or weakly connected. Due to the international nature of the study, it is not only possible to measure connection by country, but it is also possible to compare connection between countries. The 14 countries studied were China, Japan, the U.S., Russia, Germany, Great Britain, France, Spain, South Africa, Argentina, Isr...


More From BioPortfolio on "International Randomized Study to Compare CyberKnife Stereotactic Radiotherapy With Surgical Resection In Stage I Non-small Cell Lung Cancer"

Quick Search

Corporate Database Quicklinks